Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
9/2017 not set
NTB Pharma
NTB Pharma Overview
NTB Pharma seeks to develop novel targets for immuno-oncology and cancer immunotherapy utilizing the SLAM family receptors. NTB Pharma hypothesizes that SLAMF6, a highly potent agonistic receptor on immune cells, is a natural candidate for anti-melanoma immunotherapy. Its uniqueness may lie in a dual action on lymphocytes and myeloid-derived suppressor cells, augmenting T-cell function and reversing the deleterious effect of the tumor environment. NTB Pharma was established based on a technology developed in the laboratory of Prof. Lotem at Hadassah Medical Center, Jerusalem.